Lineage Cell Therapeutics, Inc. Finance Lease, Right-of-Use Asset, Amortization
Lineage Cell Therapeutics, Inc. (LCTX) reported Finance Lease, Right-of-Use Asset, Amortization of $8.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-06
- Lineage Cell Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $8.00K, a 42.86% decline year-over-year.
- Lineage Cell Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $13.00K, a 7.14% decline year-over-year.
- Lineage Cell Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $16.00K, a 14.29% increase year-over-year.
- Lineage Cell Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $15.00K, a 15.38% increase year-over-year.
- Lineage Cell Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2025 was $59.00K, a 7.27% increase from fiscal 2024.
- Lineage Cell Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2024 was $55.00K, a 99.89% decline from fiscal 2023.
- Lineage Cell Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2023 was $50.00M, a 357042.86% increase from fiscal 2022.
- Lineage Cell Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2022 was $14.00K, a 0.00% change from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month | Finance Lease, Right-of-Use Asset, Amortization 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $8.00K 10-Q · filed 2026-08-06 | $21.00K 10-Q · filed 2026-08-06 | $37.00K derived: sum of 3 quarters · filed 2026-08-06 | $52.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $13.00K 10-Q · filed 2026-05-12 | $29.00K derived: sum of 2 quarters · filed 2026-05-12 | $44.00K derived: sum of 3 quarters · filed 2026-05-12 | $58.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $31.00K derived: sum of 2 quarters · filed 2026-03-05 | $45.00K derived: sum of 3 quarters · filed 2026-08-06 | $59.00K 10-K · filed 2026-03-05 | |
| 2025-09-30 | $15.00K 10-Q · filed 2025-11-06 | $29.00K derived: sum of 2 quarters · filed 2026-08-06 | $43.00K 10-Q · filed 2025-11-06 | $57.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $14.00K 10-Q · filed 2026-08-06 | $28.00K 10-Q · filed 2026-08-06 | $42.00K derived: sum of 3 quarters · filed 2026-08-06 | $55.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $14.00K 10-Q · filed 2026-05-12 | $28.00K derived: sum of 2 quarters · filed 2026-05-12 | $41.00K derived: sum of 3 quarters · filed 2026-05-12 | $55.00K derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $27.00K derived: sum of 2 quarters · filed 2026-03-05 | $41.00K derived: sum of 3 quarters · filed 2026-03-05 | $55.00K 10-K · filed 2026-03-05 | $55.00M 10-K · filed 2025-03-10 |
| 2024-09-30 | $13.00K 10-Q · filed 2025-11-06 | $27.00K derived: sum of 2 quarters · filed 2025-11-06 | $41.00K 10-Q · filed 2025-11-06 | $50.00M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $14.00K 10-Q · filed 2025-08-12 | $28.00K 10-Q · filed 2025-08-12 | $49.99M derived: sum of 3 quarters · filed 2025-08-12 | $50.01M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $14.00K 10-Q · filed 2025-05-13 | $49.98M derived: sum of 2 quarters · filed 2025-05-13 | $49.99M derived: sum of 3 quarters · filed 2025-05-13 | $50.00M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $49.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $49.98M derived: sum of 2 quarters · filed 2025-03-10 | $49.99M derived: sum of 3 quarters · filed 2025-03-10 | $50.00M 10-K · filed 2025-03-10 | $50.00K 10-K · filed 2024-03-07 |
| 2023-09-30 | $14.00K 10-Q · filed 2024-11-14 | $27.00K derived: sum of 2 quarters · filed 2024-11-14 | $37.00K 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $13.00K 10-Q · filed 2024-08-08 | $23.00K 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $10.00K 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | $14.00K 10-K · filed 2024-03-07 | ||||
| 2021-12-31 | -$5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$6.00K derived: sum of 2 quarters · filed 2022-03-10 | $4.00K derived: sum of 3 quarters · filed 2022-03-10 | $14.00K 10-K · filed 2022-03-10 | |
| 2021-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $9.00K derived: sum of 2 quarters · filed 2021-11-10 | $19.00K 10-Q · filed 2021-11-10 | $44.00K derived: sum of 4 quarters · filed 2022-03-10 | |
| 2021-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $20.00K 10-Q · filed 2021-08-12 | $45.00K derived: sum of 3 quarters · filed 2022-03-10 | $74.00K derived: sum of 4 quarters · filed 2022-03-10 | |
| 2021-03-31 | $10.00K 10-Q · filed 2021-05-13 | $35.00K derived: sum of 2 quarters · filed 2022-03-10 | $64.00K derived: sum of 3 quarters · filed 2022-03-10 | $73.00K derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-12-31 | $25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $54.00K derived: sum of 2 quarters · filed 2022-03-10 | $63.00K derived: sum of 3 quarters · filed 2022-03-10 | $72.00K 10-K · filed 2022-03-10 | |
| 2020-09-30 | $29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $38.00K derived: sum of 2 quarters · filed 2021-11-10 | $47.00K 10-Q · filed 2021-11-10 | $117.00K derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $18.00K 10-Q · filed 2021-08-12 | $88.00K derived: sum of 3 quarters · filed 2021-08-12 | $120.00K derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $9.00K 10-Q · filed 2021-05-13 | $79.00K derived: sum of 2 quarters · filed 2021-05-13 | $111.00K derived: sum of 3 quarters · filed 2021-05-13 | $124.00K derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $70.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $102.00K derived: sum of 2 quarters · filed 2021-03-11 | $115.00K derived: sum of 3 quarters · filed 2021-03-11 | $129.00K 10-K · filed 2021-03-11 | |
| 2019-09-30 | $32.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $45.00K derived: sum of 2 quarters · filed 2020-11-04 | $59.00K 10-Q · filed 2020-11-04 | ||
| 2019-06-30 | $13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $27.00K 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $14.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |